SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mad2 who wrote (2042)1/16/2000 1:55:00 PM
From: DanZ  Read Replies (1) of 5582
 
Mad2,

It is my understanding that Agouron will be a prescription drug. I haven't seen any estimates on how much it will cost, but it faces the same issues as Pleconaril from the standpoint of prescription versus OTC. One thing that Agouron has going for it is that Warner Lambert has plenty of money to promote it. On the other hand, all the advertising in the world sometimes can't change consumer preferences. The preponderance of the population doesn't go to the doctor for the common cold and it will take a lot to change that preference...especially if Agouron is only marginally better than most OTC cold remedies, and not nearly as effective as Zicam. I don't see how a prescription drug can compete effectively with OTC remedies when the prescription drug doesn't offer any therapeutic benefits over the OTC remedies.

Best regards,

Dan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News